PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
Rebecca S KristeleitAlexandra LearyAna OakninAndres RedondoAngela GeorgeStephen ChuiAicha SeillerMario Liste-HermosoJenna WillisColby S ShemeshJim XiaoKevin K LinLuciana MolineroYinghui GuanIsabelle L Ray-CoquardLinda R MileshkinPublished in: British journal of cancer (2024)
ClinicalTrials.gov (NCT03101280).